Literature DB >> 31641223

Rapid detection and genotyping of ALK fusion variants by adapter multiplex PCR and high-resolution melting analysis.

Mei Li1, Shen Lu2, Xu Sun3.   

Abstract

Anaplastic lymphoma kinase (ALK) fusion is a promising predictive biomarker of ALK-tyrosine kinase inhibitor (ALK-TKI) treatment. Furthermore, different fusion variants correlate to different ALK-TKIs responses. Although variant identification assists in treatment direction, most ALK detection assays do not genotype different fusion variants. We developed a high-resolution melting (HRM) assay to rapidly detect ALK fusions and automatically distinguish at least 20 fusion variants in one tube. Adapter multiplex PCR was designed to amplify ALK fusion variants and the reference gene GAPDH. After HRM, negative derivative curves showed a low temperature GAPDH peak, and if an ALK fusion was present, a high temperature peak from the ALK segment and variably a middle temperature part associated with the fusion partner. Selected regions of the second derivative curves were analyzed to extract features (∆Tm, PTS/ITS, H1/H2) that define two curve types (monotonic and non-monotonic). Synthetic samples of 20 ALK fusion variants were used to train a quadratic discriminate analysis model, and the accuracy was 97.06% (66/68) and 85.71% (144/162) for monotonic and non-monotonic variants, respectively. The limit of detection of the assay was 1%. The analytical sensitivity of genotyping was 1 and 5% for monotonic and non-monotonic variants, respectively. In a blinded study, we detected ALK fusion from formalin-fixed paraffin-embedded lung cancer samples with a 100% 47) and genotyping /47) and genotyping (7/7). Multiplex adapter HRM is a simple, fast, and sensitive way of ALK fusion detection and genotyping. Automatic genotyping with parameters extracted from second derivative curves is a promising method that may be applicable to other types of gene variants detected by HRM.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31641223     DOI: 10.1038/s41374-019-0330-x

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  48 in total

1.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Authors:  Eunice L Kwak; Yung-Jue Bang; D Ross Camidge; Alice T Shaw; Benjamin Solomon; Robert G Maki; Sai-Hong I Ou; Bruce J Dezube; Pasi A Jänne; Daniel B Costa; Marileila Varella-Garcia; Woo-Ho Kim; Thomas J Lynch; Panos Fidias; Hannah Stubbs; Jeffrey A Engelman; Lecia V Sequist; WeiWei Tan; Leena Gandhi; Mari Mino-Kenudson; Greg C Wei; S Martin Shreeve; Mark J Ratain; Jeffrey Settleman; James G Christensen; Daniel A Haber; Keith Wilner; Ravi Salgia; Geoffrey I Shapiro; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

2.  Examining EML4-ALK variants in the clinical setting: the next frontier?

Authors:  Malini Patel; Jyoti Malhotra; Salma K Jabbour
Journal:  J Thorac Dis       Date:  2018-11       Impact factor: 2.895

3.  Novel ALK fusion partners in lung cancer.

Authors:  Aglaya G Iyevleva; Grigory A Raskin; Vladislav I Tiurin; Anna P Sokolenko; Natalia V Mitiushkina; Svetlana N Aleksakhina; Aigul R Garifullina; Tatiana N Strelkova; Valery O Merkulov; Alexandr O Ivantsov; Ekatherina Sh Kuligina; Kazimir M Pozharisski; Alexandr V Togo; Evgeny N Imyanitov
Journal:  Cancer Lett       Date:  2015-03-23       Impact factor: 8.679

4.  Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.

Authors:  Dong-Wan Kim; Marcello Tiseo; Myung-Ju Ahn; Karen L Reckamp; Karin Holmskov Hansen; Sang-We Kim; Rudolf M Huber; Howard L West; Harry J M Groen; Maximilian J Hochmair; Natasha B Leighl; Scott N Gettinger; Corey J Langer; Luis G Paz-Ares Rodríguez; Egbert F Smit; Edward S Kim; William Reichmann; Frank G Haluska; David Kerstein; D Ross Camidge
Journal:  J Clin Oncol       Date:  2017-05-05       Impact factor: 44.544

5.  Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  Solange Peters; D Ross Camidge; Alice T Shaw; Shirish Gadgeel; Jin S Ahn; Dong-Wan Kim; Sai-Hong I Ou; Maurice Pérol; Rafal Dziadziuszko; Rafael Rosell; Ali Zeaiter; Emmanuel Mitry; Sophie Golding; Bogdana Balas; Johannes Noe; Peter N Morcos; Tony Mok
Journal:  N Engl J Med       Date:  2017-06-06       Impact factor: 91.245

Review 6.  Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements.

Authors:  Cristina Teixidó; Niki Karachaliou; Vicente Peg; Ana Gimenez-Capitan; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2014-04

7.  Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Dara L Aisner; Maria E Arcila; Mary Beth Beasley; Eric H Bernicker; Carol Colasacco; Sanja Dacic; Fred R Hirsch; Keith Kerr; David J Kwiatkowski; Marc Ladanyi; Jan A Nowak; Lynette Sholl; Robyn Temple-Smolkin; Benjamin Solomon; Lesley H Souter; Erik Thunnissen; Ming S Tsao; Christina B Ventura; Murry W Wynes; Yasushi Yatabe
Journal:  J Mol Diagn       Date:  2018-01-23       Impact factor: 5.568

Review 8.  Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.

Authors:  Tianhong Li; Hsing-Jien Kung; Philip C Mack; David R Gandara
Journal:  J Clin Oncol       Date:  2013-02-11       Impact factor: 44.544

9.  Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Authors:  Manabu Soda; Young Lim Choi; Munehiro Enomoto; Shuji Takada; Yoshihiro Yamashita; Shunpei Ishikawa; Shin-ichiro Fujiwara; Hideki Watanabe; Kentaro Kurashina; Hisashi Hatanaka; Masashi Bando; Shoji Ohno; Yuichi Ishikawa; Hiroyuki Aburatani; Toshiro Niki; Yasunori Sohara; Yukihiko Sugiyama; Hiroyuki Mano
Journal:  Nature       Date:  2007-07-11       Impact factor: 49.962

10.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Kazuhiko Nakagawa; Takashi Seto; Lucio Crinó; Myung-Ju Ahn; Tommaso De Pas; Benjamin Besse; Benjamin J Solomon; Fiona Blackhall; Yi-Long Wu; Michael Thomas; Kenneth J O'Byrne; Denis Moro-Sibilot; D Ross Camidge; Tony Mok; Vera Hirsh; Gregory J Riely; Shrividya Iyer; Vanessa Tassell; Anna Polli; Keith D Wilner; Pasi A Jänne
Journal:  N Engl J Med       Date:  2013-06-01       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.